Injecting Tighter Regulation: Implications of the TGA's Clampdown on Cosmetic Injectables Advertising.

Abstract

Recently, the Therapeutic Goods Administration (TGA) updated its guidance on cosmetic injectables advertising. The updates confirm that all direct or indirect advertising of cosmetic injectable products, including botulinum toxins or dermal fillers, is prohibited in Australia. While some commentators have lamented these updates, they present no changes to the law. As cosmetic injectables are prescription-only medicines, they have long been subject to the statutory prohibition on direct-to-consumer advertising of medicines in Australia. The updates, however, signal a real change to the TGA's enforcement stance and attitude. In this way, the updated guidance illustrates the practical application of the TGA's responsive and risk-based approach to regulation - a focus of this column. The changes also bring into view some of the emerging dangers associated with cosmetic injectables and related cosmetic treatments. This column explores the regulation of cosmetic injectables, the TGA's changing approach, and its implications.